Abstract
Epithelial ovarian carcinoma is often diagnosed at an advanced stage of disease and is the leading cause of death from gynaecological neoplasia. The genetic changes that occur during the development of this carcinoma are poorly understood. It has been proposed that IGFIIR, TGFβ1 and TGFβRII act as a functional unit in the TGFβ growth inhibitory pathway, and that somatic loss-of-function mutations in any one of these genes could lead to disruption of the pathway and subsequent loss of cell cycle control. We have examined these 3 genes in 25 epithelial ovarian carcinomas using single-stranded conformational polymorphism analysis and DNA sequence analysis. A total of 3 somatic missense mutations were found in the TGFβRII gene, but none in IGFRII or TGFβ1. An association was found between TGFβRII mutations and histology, with 2 out of 3 clear cell carcinomas having TGFβRII mutations. This data supports other evidence from mutational analysis of the PTEN and β-catenin genes that there are distinct developmental pathways responsible for the progression of different epithelial ovarian cancer histologic subtypes. © 2001 Cancer Research Campaign www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Cardillo, MR, Yap, E & Castagna, G (1997a). Molecular genetic analysis of TGF-β1 in ovarian neoplasia. J Exp Clin Cancer Res, 16, 49–56.
Cardillo, MR, Yap, E & Castagna, G (1997b). Molecular genetic analysis of TGFβ1 in breast cancer. J Exp Clin Cancer Res, 16, 57–63.
Cardillo, MR & Yap, E (1997). TGF-β1 in colonic neoplasia: a genetic molecular and immunohistochemical study. J Exp Clin Cancer Res, 16, 281–288.
Chen, R-H & Derynck, R (1994). Homomeric interactions between type II transforming growth factor-beta receptors. J Biol Chem, 269, 22861–22874.
Chenevix-Trench, G, Leary, J, Kerr, J, Michel, J, Kefford, R, Hurst, T, Parsons, P, Friedlander, M & Khoo, S-K (1992). Frequent loss of heterozygosity on chromosome 18 in ovarian adenocarcinoma which does not always include the DCC locus. Oncogene, 7, 1059–1065.
Chenevix-Trench, G, Kerr, J, Hurst, T, Shih, Y-C, Purdie, D, Bergman, L, Friedlander, M, Sanderson, B, Zournazi, A, Coombs, T, Leary, JA, Crawford, E, Shelling, AN, Cooke, I, Ganesan, TS, Searle, J, Choi, C, Barrett, JC, Khoo, S-K & Ward, B (1997). Analysis of loss of heterozygosity and KRAS2 mutations in ovarian neoplasms: clinicopathological correlations. Genes Chromosomes Cancer, 18, 75–83.
Cooke, I, Shelling, AN, Le Meuth, VG, Charnock, ML & Ganesan, TS (1996). Allele loss on chromosome arm 6q and fine mapping of the region at 6q27 in epithelial ovarian cancer. Genes Chromosomes Cancer, 15, 223–233.
De Souza, AT, Hankins, GR, Washington, MK, Fine, RL, Orton, TC & Jirtle, RI (1995a). Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene, 10, 1725–1729.
De Souza, AT, Hankins, GR, Washington, MK, Orton, TC & Jirtle, RL (1995b). M6P/IGF2R gene is mutated in human hepatocellular carcinomas with loss of heterozygosity. Nature Genet, 11, 447–449.
Garrigue-Antar, L, Muñoz-Antonia, T, Antonia, SJ, Gesmonde, J, Vellucci, VF & Reiss, M (1995). Missense mutations of the transforming growth factor β type II receptor in human head and neck squamous carcinoma cells. Cancer Res, 55, 3982–3987.
Gerdes, MJ, Larsen, M, McBride, L, Dang, TD, Lu, B & Rowley, DR (1998). Localisation of transforming growth factor-beta(1) and type II receptor in developing normal human prostate and carcinoma tissues. J Histochem Cytochem, 46, 379–388.
Goff, BA, Sainz de la Cuesta, R, Muntz, HG, Fleischhacker, D, Ek, M, Rice, LW, Nikrui, N, Tamini, HK, Cain, JM, Greer, BE & Fuller, AF (1996). Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol, 60, 412–417.
Guo, Y & Kyprianou, N (1998). Overexpression of transforming growth factor (TGF) betal type II receptor restores TGF-betal sensitivity and signaling in human prostate cancer cells. Cell Growth Differ, 9, 185–193.
Haber, DA & Fearon, ER (1998). The promise of cancer genetics. Lancet, 351, 1–8.
Hollstein, M, Sidransky, D, Volgelstein, B & Harris, CC (1991). p53 mutations in human cancers. Science, 253, 49–53.
Jirtle, RL, Hankins, GR, Reisenbichler, H & Boyer, IJ (1994). Regulation of mannose 6-phosphate/insulin-like growth factor-II receptors and transforming growth factor beta during liver tumor promotion with phenobarbital. Carcinogenesis, 15, 1473–1478.
Landis, S, Murray, T, Bolden, S & Wingo, PA (1998). Cancer statistics, 1998. CA Cancer J Clin, 48, 6–29.
Lynch, MA, Nakashima, R, Song, HJ, Degroff, VL, Wang, D, Enomoto, T & Weghorst, CM (1998). Mutational analysis of the transforming growth factor beta receptor type II gene in human ovarian carcinoma. Cancer Res, 58, 4227–4232.
Makar, AP, Baekelandt, M, Trope, CG & Kristensen, GB (1995). The prognostic significance of residual disease, FIGO substage, tumour histology, and grade in patients with FIGO stage III ovarian cancer. Gynecol Oncol, 56, 175–180.
Munger, JS, Harpel, JG, Gleizes, PE, Mazzieri, R, Nunes, I & Rifkin, DB (1997). Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney Int, 51, 1376–1382.
Obata, K, Morland, SJ, Watson, RH, Hitchcock, A, Chenevix-Trench, G, Thomas, EJ & Cambell, IG (1998). Frequent Pten/Mmac mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res, 58, 2095–2097.
Orita, M, Iwahana, H, Kanazawa, H, Hayashi, K & Sekiya, T (1989). Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Nat Acad Sci USA, 86, 2766–2770.
Polyak, K (1996). Negative regulation of cell growth by TGF β. Biochim Biophys Acta, 1242, 185–199.
Rich, JN, Zhang, M, Datto, MB, Bigner, DD & Wang, X (1999). Transforming growth factor-β-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma lines. J Biol Chem, 274, 35053–35058.
Roux, KH (1995). Optimisation and troubleshooting in PCR. Diffenbach CW, Dveksler GS (eds) PCR Primer: a Laboratory Manual, CSHL Press: New York
Tammella, J, Geisler, JP, Eskew, PN & Geisler, HE (1998). Clear cell carcinoma of the ovary: poor prognosis compared to serous carcinoma. Eur J Gynaecol Oncol, 19, 438–440.
Taylor, S, Knighton, DR, Zheng, J, ten Eyck, LF & Sowadski, JM (1992). Structural framework for the protein kinase family. Ann Rev Cell Biol, 8, 429–462.
ten Dijke, P & Heldin, C-H (1999). An anchor for activation. Nature, 397, 109–111.
Tsukazaki, T, Chiang, T, Davidson, A, Attisano, L & Wrana, J (1998). SARA, a FYVE domain protein that recruits Smad2 to the TGFβ receptor. Cell, 95, 779–791.
Vincent, F, Hagiwara, K, Ke, Y, Stoner, GD, Demetrick, DJ & Bennett, WP (1996). Mutation analysis of the transforming growth factor beta type II receptor in sporadic human cancers of the pancreas, liver, and breast. Biochem Biophys Res Commun, 223, 561–564.
Wang, D, Song, H, Evans, JA, Lang, JC, Schuller, DE & Weghorst, CM (1997). Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck. Carcinogenesis, 18, 2285–2290.
Wang, D, Kanuma, T, Mizunuma, H, Takama, F, Ibuki, Y, Wake, N, Mogi, A, Shitara, Y & Takenoshita, S (2000). Analysis of specific gene mutations in the transforming growth factor-beta signal transduction pathway in human ovarian cancer. Cancer Res, 60, 4507–4512.
Wright, K, Wilson, P, Morland, S, Campbell, I, Walsh, M, Hurst, T, Ward, B, Cummings, M & Chenevix-Trench, G (1999). β-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer, 82, 625–629.
Yan, Z, Winawer, S & Friedman, E (1994). Two different signal transduction pathways can be activated by transforming growth factor β1 in epithelial cells. J Biol Chem, 269, 13231–13237.
Zhang, F, Strand, A, Robbins, D, Cobb, MH & Goldsmith, EJ (1994). Atomic structure of the MAP kinase ERK2 at 2.3å resolution. Nature, 367, 704–711.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Francis-Thickpenny, K., Richardson, D., Ee, C. et al. Analysis of the TGF β functional pathway in epithelial ovarian carcinoma. Br J Cancer 85, 687–691 (2001). https://doi.org/10.1054/bjoc.2001.1950
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1950
Keywords
This article is cited by
-
Atractylenolide I modulates ovarian cancer cell-mediated immunosuppression by blocking MD-2/TLR4 complex-mediated MyD88/NF-κB signaling in vitro
Journal of Translational Medicine (2016)
-
Homeodomain protein DLX4 counteracts key transcriptional control mechanisms of the TGF-β cytostatic program and blocks the antiproliferative effect of TGF-β
Oncogene (2011)
-
Intrahepatic cholangiocarcinoma escapes from growth inhibitory effect of transforming growth factor-β1 by overexpression of cyclin D1
Laboratory Investigation (2005)